| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/15/2006 | CA2589921A1 Composition for proteasome inhibition |
| 06/15/2006 | CA2589920A1 Small molecule inhibitors of bacterial dam dna methyl transferases |
| 06/15/2006 | CA2589864A1 12-aryl prostaglandin analogs |
| 06/15/2006 | CA2589828A1 Compositions comprising a taxoid and a benzimidazole carbamate for the treatment of cancer |
| 06/15/2006 | CA2589746A1 Methods for diagnosis and treatment of crohn's disease |
| 06/15/2006 | CA2589718A1 Tetrazolyl-methylene amino acid derivatives |
| 06/15/2006 | CA2589699A1 Process for the preparation of carvedilol and its enantiomers |
| 06/15/2006 | CA2589655A1 Treatment with omega-3 fatty acids and ppar agonist and/or antagonist and a combination product thereof |
| 06/15/2006 | CA2589654A1 Omega-3 fatty acids and dyslipidemic agent for lipid therapy |
| 06/15/2006 | CA2589448A1 Substituted imidazo[4,5-b]pyridines as inhibitors of gastric acid secretion |
| 06/15/2006 | CA2589274A1 Inhibitors of protein kinases |
| 06/15/2006 | CA2589271A1 Urea inhibitors of map kinases |
| 06/15/2006 | CA2589202A1 Use of staurosporine derivatives for the treatment of multiple myeloma |
| 06/15/2006 | CA2589196A1 Malonamide derivatives as inhibitors of gamma-secretase for the treatment of alzheimer's disease |
| 06/15/2006 | CA2589192A1 Phenyl-piperazin methanone derivatives |
| 06/15/2006 | CA2589127A1 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors |
| 06/15/2006 | CA2588994A1 Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| 06/15/2006 | CA2588979A1 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators |
| 06/15/2006 | CA2588764A1 Macrocyclic quinazole derivatives and their use as mtki |
| 06/15/2006 | CA2588761A1 2,4(4,6)pyrimidine derivatives |
| 06/15/2006 | CA2588760A1 Substituted tetracyclic tetrahydropyran, pyrrolidine and tetrahydrothiophene derivatives |
| 06/15/2006 | CA2588633A1 Novel anthranilic acid derivative or salt thereof |
| 06/15/2006 | CA2588587A1 Cytotoxic agents comprising new taxanes |
| 06/15/2006 | CA2588270A1 Methods and compositions for treating ocular disorders |
| 06/15/2006 | CA2588148A1 1-phenyl-3-piperazine-pyrazoles and pesticidal compositions of matter thereof |
| 06/15/2006 | CA2587940A1 Benzdioxane piperazine derivatives with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites |
| 06/15/2006 | CA2587936A1 Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-d2 receptors and serotonin reuptake sites |
| 06/15/2006 | CA2587928A1 Phenylpiperazines with a combination of affinity for dopamine -d2 receptors and serotonin reuptake sites |
| 06/15/2006 | CA2587788A1 3, 6-bicyclolides |
| 06/15/2006 | CA2587749A1 Piperidine derivative and process for producing the same |
| 06/15/2006 | CA2587559A1 Aryloxyethylamine derivatives with a combination of partial d0pamine-d2 receptor agonism and serotonin reuptake inhibition |
| 06/15/2006 | CA2587523A1 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
| 06/15/2006 | CA2587516A1 Treatment and prevention of epilepsy |
| 06/15/2006 | CA2587508A1 Novel spirotropane compounds and methods for the modulation of chemokine receptor activity |
| 06/15/2006 | CA2587381A1 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition |
| 06/15/2006 | CA2587357A1 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition |
| 06/15/2006 | CA2587318A1 Pyrrolidin-2-one derivatives for use as dp1 receptor agonists |
| 06/15/2006 | CA2587202A1 Phenylpiperazine derivatives with a combination of partial dopamine-d2 receptor agonism and serotonin reuptake inhibition |
| 06/15/2006 | CA2586991A1 Substituted indoles, compositions containing them, method for the production thereof and their use |
| 06/15/2006 | CA2586597A1 Multiparticulate pharmaceutical form comprising mucoadhesively formulated nucleic acid active ingredients, and a process for producing the pharmaceutical form |
| 06/15/2006 | CA2586288A1 Oral suspension comprising meloxicam |
| 06/15/2006 | CA2584307A1 Indane amides with antiproliferative activity |
| 06/14/2006 | EP1669462A1 Method of preparing alpha-glycosylisoquercitrin, intermediate therefor and by-product |
| 06/14/2006 | EP1669458A1 Process for producing 1,4-dihydoxy-2-naphthoic acid |
| 06/14/2006 | EP1669450A1 Staple type oligonucleotide and drug comprising the same |
| 06/14/2006 | EP1669379A1 3,5-dimethyl-1-adamantyl-ammonium polymeric salts and the use thereof in the form of antiviral agents |
| 06/14/2006 | EP1669366A1 Lipids comprising an aminoxy group |
| 06/14/2006 | EP1669364A2 Methods and compositions for treating hepatitis C virus |
| 06/14/2006 | EP1669357A1 SUBSTANCE WHICH EXHIBITS ANTIVIRAL AND ANTIBACTERIAL ACTIVITY AND IS BASED ON DERIVATIVES OF 2,8-DITHIOXO-1H-PYRANO 2,3D&cedi l;6,5-D DIPYRIMIDYNE AND 10-AZA-ANALOGUE THEREOF |
| 06/14/2006 | EP1669356A1 CCR1 Antagonists for the treatment of i.a demyelinating inflammatory disease |
| 06/14/2006 | EP1669354A1 8-cyanoquinolonecarboxylic acid derivative |
| 06/14/2006 | EP1669350A1 Novel piperidine derivative |
| 06/14/2006 | EP1669348A1 Novel antifungal agent comprising heterocyclic compound |
| 06/14/2006 | EP1669338A1 Process for producing product containing proanthocyanidin in high proportion |
| 06/14/2006 | EP1669092A1 Preparation for the prophylaxis of restenose |
| 06/14/2006 | EP1669091A2 Therapeutic inhibitor of vascular smooth muscle cells |
| 06/14/2006 | EP1669090A1 Bitterness-masking particulate jelly beverage |
| 06/14/2006 | EP1669087A1 Preparation containing basic drug |
| 06/14/2006 | EP1669080A1 Method of inhibiting alveolar resorption and peridental membrane loss and composition for internal use to be used therein |
| 06/14/2006 | EP1669079A1 Composition of SSAO substrates and metal compounds of the Vla Vlb groups of the periodic table |
| 06/14/2006 | EP1669078A1 Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside RB 1 |
| 06/14/2006 | EP1669077A1 Antibacterial compositions of n-acetyl-d-aminoglycosamine and antibiotics |
| 06/14/2006 | EP1669076A1 Use of n-acetyl-d-aminoglycosamine in preparation of drugs for modulating microorganisms on mucous membrane |
| 06/14/2006 | EP1669075A1 Therapeutic agent for ageing macular degeneration |
| 06/14/2006 | EP1669074A1 Use of megestrol acetate for improving heart function and the treatment of heart insufficiency |
| 06/14/2006 | EP1669073A2 Fulvestrant formulation |
| 06/14/2006 | EP1669072A1 Benzothiazine and benzothiadiazine derivatives, process for their preparation and phamaceutical compositions containing them |
| 06/14/2006 | EP1669071A1 Pyrrolotriazine inhibitors of kinases |
| 06/14/2006 | EP1669070A2 2-imino-thiazolidine and -oxazolidine derivatives for use as antiinflammatory agents |
| 06/14/2006 | EP1669069A1 Compounds effecting glukokinase |
| 06/14/2006 | EP1669068A1 Compounds effecting Glucokinase |
| 06/14/2006 | EP1669067A2 Flavonoids for cystic fibrosis therapy |
| 06/14/2006 | EP1669066A1 Infusion preparation containing (2r)-2-propyloctanoic acid as the active ingredient |
| 06/14/2006 | EP1669065A1 Drug containing (2r)-2-propyloctanoic acid as the active ingredient |
| 06/14/2006 | EP1669064A1 Composition and method of a topical therapy of neurodermatitis |
| 06/14/2006 | EP1669063A1 Transdermal therapeutic systems for administering rotigotine |
| 06/14/2006 | EP1668985A2 Nucleophile substituted ecteinascidins and N-oxide ecteinascidins |
| 06/14/2006 | EP1668424A2 Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents |
| 06/14/2006 | EP1668362A2 Cytoplasmic activity of retinoid x receptor and its regulation by ligands and dimerization |
| 06/14/2006 | EP1668337A2 Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics |
| 06/14/2006 | EP1668145A2 SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION |
| 06/14/2006 | EP1668132A1 Cytokine involved in epithelial-mesenchymal transition |
| 06/14/2006 | EP1668128A1 Treatment of menorrhagia, dysmenorrhoea or endometriosis |
| 06/14/2006 | EP1668116A1 Methods for enhancing embryo viability |
| 06/14/2006 | EP1668024A2 Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
| 06/14/2006 | EP1668020A2 Novel adenosine a sb 3 /sb receptor agonists |
| 06/14/2006 | EP1668017A1 Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof |
| 06/14/2006 | EP1668016A1 Ligands |
| 06/14/2006 | EP1668014A2 Fused heterocyclic compounds as serotonin receptor modulators |
| 06/14/2006 | EP1668013A1 Pyrazolopyrrole derivatives as protein kinase inhibitors |
| 06/14/2006 | EP1668011A2 Hiv replication inhibiting purine derivatives |
| 06/14/2006 | EP1668010A2 Method of preparing 4-amino-1h -imidazo(4,5- c )quinolines and acid addition salts thereof |
| 06/14/2006 | EP1668009A1 Hcv inhibitors and methods of using them |
| 06/14/2006 | EP1668008A2 Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use |
| 06/14/2006 | EP1668006A1 Quinazoline derivatives as antiproliferative agents |
| 06/14/2006 | EP1668005A1 Acyloxymethylcarbamate prodrugs of oxazolidinones |
| 06/14/2006 | EP1668004A1 Benzoxazole acetonitriles |
| 06/14/2006 | EP1668003A1 Benzisoxazoles |
| 06/14/2006 | EP1668002A2 2,4-dioxo-3-quinazolinylaryl sulfonylureas |
| 06/14/2006 | EP1668001A1 Substituted heteroaryl benzofuran acids |